A 2025 multicenter, propensity-matched trial has provided a head-to-head comparison between G-POEM and Laparoscopic Gastric Electrical Stimulation (GES). The study found that G-POEM yielded significantly lower operative times (approx. 29 minutes vs. 96 minutes) and shorter hospital stays (0.5 days vs. 2.4 days) compared to the implantation of the Enterra system. Furthermore, symptom recurrence was notably lower following G-POEM (41.6% vs. 78.8% for GES over a 12-month period).

While GES remains a valuable tool for diabetic patients with intractable vomiting, the "functional improvement" scores for G-POEM were consistently higher across all etiologies. Technical details regarding the device malfunctions and battery replacement cycles associated with GES are documented in the Gastroparesis Treatment Market industry outlook. These findings are reshaping the "procedural ladder," suggesting that endoscopic myotomy should be considered earlier in the treatment algorithm for medically refractory patients.